RenovoRx (RNXT) Competitors $1.02 +0.02 (+2.00%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends RNXT vs. CYTH, IKT, NNVC, FGEN, CALC, ACAB, ONCY, IFRX, PWUP, and BYSIShould you be buying RenovoRx stock or one of its competitors? The main competitors of RenovoRx include Cyclo Therapeutics (CYTH), Inhibikase Therapeutics (IKT), NanoViricides (NNVC), FibroGen (FGEN), CalciMedica (CALC), Atlantic Coastal Acquisition Corp. II (ACAB), Oncolytics Biotech (ONCY), InflaRx (IFRX), PowerUp Acquisition (PWUP), and BeyondSpring (BYSI). RenovoRx vs. Cyclo Therapeutics Inhibikase Therapeutics NanoViricides FibroGen CalciMedica Atlantic Coastal Acquisition Corp. II Oncolytics Biotech InflaRx PowerUp Acquisition BeyondSpring RenovoRx (NASDAQ:RNXT) and Cyclo Therapeutics (NASDAQ:CYTH) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, community ranking, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations. Does the media refer more to RNXT or CYTH? In the previous week, RenovoRx's average media sentiment score of 0.00 equaled Cyclo Therapeutics'average media sentiment score. Company Overall Sentiment RenovoRx Neutral Cyclo Therapeutics Neutral Which has better earnings & valuation, RNXT or CYTH? RenovoRx has higher earnings, but lower revenue than Cyclo Therapeutics. RenovoRx is trading at a lower price-to-earnings ratio than Cyclo Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRenovoRxN/AN/A-$10.23M-$0.60-1.70Cyclo Therapeutics$1.08M19.18-$20.06M-$0.88-0.82 Does the MarketBeat Community believe in RNXT or CYTH? Cyclo Therapeutics received 2 more outperform votes than RenovoRx when rated by MarketBeat users. Likewise, 71.43% of users gave Cyclo Therapeutics an outperform vote while only 44.44% of users gave RenovoRx an outperform vote. CompanyUnderperformOutperformRenovoRxOutperform Votes844.44% Underperform Votes1055.56% Cyclo TherapeuticsOutperform Votes1071.43% Underperform Votes428.57% Is RNXT or CYTH more profitable? RenovoRx has a net margin of 0.00% compared to Cyclo Therapeutics' net margin of -1,830.27%. RenovoRx's return on equity of -410.14% beat Cyclo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets RenovoRxN/A -410.14% -151.52% Cyclo Therapeutics -1,830.27%-2,741.89%-269.95% Do analysts rate RNXT or CYTH? RenovoRx presently has a consensus target price of $6.13, suggesting a potential upside of 500.49%. Cyclo Therapeutics has a consensus target price of $0.95, suggesting a potential upside of 31.65%. Given RenovoRx's stronger consensus rating and higher possible upside, research analysts clearly believe RenovoRx is more favorable than Cyclo Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RenovoRx 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Cyclo Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has more volatility and risk, RNXT or CYTH? RenovoRx has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500. Comparatively, Cyclo Therapeutics has a beta of -0.38, indicating that its stock price is 138% less volatile than the S&P 500. Do institutionals & insiders have more ownership in RNXT or CYTH? 3.1% of RenovoRx shares are held by institutional investors. Comparatively, 68.6% of Cyclo Therapeutics shares are held by institutional investors. 7.1% of RenovoRx shares are held by insiders. Comparatively, 29.8% of Cyclo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryRenovoRx beats Cyclo Therapeutics on 9 of the 15 factors compared between the two stocks. Ad Timothy SykesCountdown to the biggest trade of my 25 yr careerTim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… Breaking down the ONE MOVE you must make before the November 5th election to set yourself up for a prosperous 2025.Click here to see the surprising reason why Get RenovoRx News Delivered to You Automatically Sign up to receive the latest news and ratings for RNXT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNXT vs. The Competition Export to ExcelMetricRenovoRxPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.47M$7.03B$5.40B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-1.709.93115.5615.18Price / SalesN/A381.421,484.3492.77Price / CashN/A47.3439.6634.07Price / Book-3.645.324.665.02Net Income-$10.23M$153.56M$119.06M$225.46M7 Day Performance13.33%0.11%0.80%0.37%1 Month Performance1.49%15.22%5.65%3.57%1 Year Performance0.99%41.14%36.76%29.44% RenovoRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNXTRenovoRx1.683 of 5 stars$1.02+2.0%$6.13+500.5%-3.8%$24.47MN/A-1.706Positive NewsCYTHCyclo Therapeutics2.7002 of 5 stars$0.74-0.5%$0.95+28.2%-25.2%$21.20M$1.13M-0.849Gap DownIKTInhibikase Therapeutics2.3092 of 5 stars$2.72+12.4%$5.00+83.8%+210.6%$20.29M$260,000.00-0.948High Trading VolumeNNVCNanoViricidesN/A$1.51+1.0%N/A+26.8%$17.84MN/A-2.1620Gap UpFGENFibroGen2.8596 of 5 stars$0.30-1.4%N/A-41.7%$30.22M$173.82M-0.18486Upcoming EarningsAnalyst ForecastShort Interest ↓CALCCalciMedica3.4648 of 5 stars$3.99-1.0%$20.67+418.0%+63.3%$42.89MN/A-2.8530Insider BuyingShort Interest ↓News CoverageACABAtlantic Coastal Acquisition Corp. IIN/A$11.50+3.0%N/A+9.0%$93.92MN/A0.004High Trading VolumeONCYOncolytics Biotech2.0702 of 5 stars$1.21-0.8%$4.00+230.6%-27.2%$93.26MN/A-4.3230Positive NewsIFRXInflaRx3.4101 of 5 stars$1.58+0.6%$13.50+754.4%-2.5%$93.03M$70,000.00-1.7860Upcoming EarningsShort Interest ↓News CoveragePWUPPowerUp AcquisitionN/A$11.69+1.1%N/A-3.3%$90.83MN/A0.00N/ANews CoveragePositive NewsBYSIBeyondSpringN/A$2.31+2.2%N/A+120.4%$90.16M$1.88M0.0080Positive News Related Companies and Tools Related Companies CYTH Alternatives IKT Alternatives NNVC Alternatives FGEN Alternatives CALC Alternatives ACAB Alternatives ONCY Alternatives IFRX Alternatives PWUP Alternatives BYSI Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RNXT) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RenovoRx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RenovoRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RNXT Stock Alerts